AlphAIAlphAI — Financial news for AI agents
investing.comOCT 92 min read$JNJ

J&J’s Icotyde shows sustained psoriasis clearance at two years

Johnson & Johnson (JNJ) presented two-year data from its Phase 3 ICONIC-LEAD study of Icotyde for psoriasis, showing sustained skin clearance and safety. The drug is approved in the U.S., Europe, Japan, and China. JNJ shares rose 15% premarket. Icotyde is also being studied for other conditions.

Original reporting
investing.com
Published Oct 9, 2026, 11:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 11:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$JNJ
Bullish
high confidence
Mentioned
$JNJ
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$JNJBullishMed
01

Why it matters

The data could prompt analysts to raise earnings forecasts and may trigger a short‑term rally in JNJ shares.

02

Market read

First‑report of pivotal trial data for a large‑cap pharma stock; likely to influence both the stock and the dermatology biotech space.

03

What to watch

Potential competition from emerging biologics and the need for regulatory filings could delay commercial impact.

Relevance 8/10Novelty 9/10Timing: premarket today

Background

The article reports fresh Phase 3 trial outcomes for Icotyde, a J&J‑owned psoriasis drug, with no prior public release of these two‑year results.

Company-level read

Ticker impact

$JNJBullishHigh confidence
Context

Johnson & Johnson presented new two‑year Phase 3 ICONIC‑LEAD data for Icotyde showing 72% PASI‑90 and 44% PASI‑100 responses.

Expected impact

upward pressure as the market prices in the strong efficacy data.

Evidence & confidence

Large‑cap JNJ with a novel psoriasis therapy showing durable clearance; data may accelerate sales outlook and drive near‑term price gains.

Market effects

Sector

Strengthens the broader biotech/dermatology sector as a benchmark for long‑term psoriasis treatments.

Regional

U.S. and European markets may see modest gains in healthcare indices.

Global

Highlights J&J's global rollout potential, supporting worldwide pharma sentiment.

Counterpoint

What could challenge this read

If pricing or reimbursement challenges arise, the data may not translate into revenue, limiting upside.

Key entities

  • company
    Johnson & Johnson

    U.S. health‑care conglomerate presenting the trial data.

  • company
    Protagonist Therapeutics

    Co‑discoverer of Icotyde, partner in development rights.

Read at source← All news

StoryJohnson & Johnson reports two‑year Phase 3 results for ICOTYDE in plaque psoriasis

Related articles

OCT 9
$JNJMed

Johnson & Johnson Reports Sustained Two-Year ICOTYDE Results In Plaque Psoriasis

Johnson & Johnson (JNJ) reported two-year results from its Phase 3 ICONIC-LEAD study of ICOTYDE for plaque psoriasis, showing sustained skin clearance and symptom improvements. At Week 112, 72% of patients achieved PASI 90, 70% had clear/almost clear skin, and 44% had complete clearance. Safety findings were consistent with the drug's profile. JNJ is also studying ICOTYDE for other conditions. JNJ closed at $256.48, down 0.76%, and was down 0.15% in premarket trading.

rttnews.com2 min
OCT 9
$JNJMed

Johnson & Johnson Reports Positive Two-Year Data on ICOTYDE for

Johnson & Johnson (JNJ) reported positive two-year Phase 3 trial results for ICOTYDE, an oral peptide for plaque psoriasis, with 72% of patients achieving significant skin improvement. The company offers a 1.98% dividend yield, a 55% payout ratio, and a 4.9% 3-year dividend growth rate, but its stock is 32% overvalued relative to its GF Value. JNJ has a GF Score of 83/100, indicating strong financial health and profitability, though insider activity shows significant net selling.

gurufocus.com3 min
OCT 9
$JNJMed

At two years, at least 70% of patients on Johnson & Johnson’s psoriasis pill had clear or almost clear skin.

Johnson & Johnson (JNJ) reported two-year Phase 3 data for ICOTYDE in treating plaque psoriasis, showing 72% of patients achieved 90% skin improvement and 70% had clear/almost clear skin. Retreatment data showed 85% response recovery. No new safety issues were found. ICOTYDE is approved in major markets. Additional studies are ongoing for psoriasis, psoriatic arthritis, and inflammatory bowel diseases.

stocktitan.net3 min
OCT 9
$JNJMed

New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis

Johnson & Johnson (JNJ) presented two-year Phase 3 data for ICOTYDE® (icotrokinra) at Fall Clinical Dermatology 2026. The study showed high, sustained response rates in adults and adolescents with plaque psoriasis, with 72% achieving clear or almost clear skin and a favorable safety profile. ICOTYDE is the first targeted oral peptide blocking the IL-23 receptor. The company highlights its potential as a first-line systemic therapy.

prnewswire.com2 min